Investigations of antisense oligonucleotides targeted against bcl-2 RNAs

S Kitada1, T Miyashita, S Tanaka

  • 1La Jolla Cancer Research Foundation, Cancer Research Center, California.

Antisense Research and Development
|January 1, 1993
PubMed

Insights

An antisense oligonucleotide targeting bcl-2 mRNA effectively reduced Bcl-2 protein production in cancer cells. This bcl-2 (B-cell lymphoma 2) targeting strategy shows promise for cancer therapy by inhibiting cell survival proteins.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Antisense Technology

Background:

  • Deregulation of the bcl-2 gene, often due to t(14;18) translocations, is common in non-Hodgkin lymphomas.
  • Overexpression of bcl-2 contributes to cellular resistance to chemotherapy and radiation, making it a key target for cancer therapeutics.
  • bcl-2 protein regulates cellular survival, and its modulation is critical for developing novel cancer treatment strategies.

Purpose of the Study:

  • To investigate the efficacy of a novel 18-mer phosphodiester antisense (AS) oligonucleotide targeting the bcl-2 mRNA.
  • To assess the specificity and effectiveness of the AS oligomer in inhibiting bcl-2 protein synthesis in vitro and in cell cultures.
  • To evaluate the potential of bcl-2 antisense therapy for cancer treatment.

Main Methods:

  • In vitro protein synthesis inhibition assays using RNAse-H-supplemented reticulocyte lysates and bcl-2 mRNA.
  • Testing of the bcl-2 AS oligomer and a scrambled control (SC) oligomer on NIH-3T3 fibroblasts and t(14;18)-positive lymphoma cells (SU-DHL-4).
  • Quantification of bcl-2 mRNA and protein levels using immunoblotting and assessment of specificity against other mitochondrial proteins.

Main Results:

  • The bcl-2 AS oligomer completely abolished in vitro bcl-2 protein synthesis at 10 microM, showing specificity against mismatched RNA.
  • Concentration-dependent reductions in Bcl-2 protein levels were observed in NIH-3T3 and SU-DHL-4 cells treated with the AS oligomer, but not the SC oligomer.
  • Treatment of SU-DHL-4 cells with 200 microM AS oligomer resulted in 84-95% reduction in Bcl-2 protein, with minimal impact on other control proteins, and led to mRNA loss within 1 day, with protein reduction apparent by 3 days.

Conclusions:

  • The bcl-2 antisense oligonucleotide is a specific and effective inhibitor of bcl-2 protein production.
  • This study demonstrates the potential of antisense technology targeting bcl-2 for developing novel cancer therapies.
  • The findings support bcl-2 as a viable therapeutic target in lymphomas and other cancers characterized by its overexpression.